Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers

PIK3CA Mutations and PTEN Loss in Salivary Duct Carcinomas

(2013) Christopher C. Griffith et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours

(2013) J. Cros et al.   ANNALS OF ONCOLOGY

Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer

(2013) John M. Fitzpatrick et al.   EUROPEAN UROLOGY

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

(2012) V. Nardi et al.   CLINICAL CANCER RESEARCH

The androgen/androgen receptor axis in prostate cancer

(2012) Eric G. Bluemn et al.   CURRENT OPINION IN ONCOLOGY

Rare cancers of the head and neck area in Europe

(2011) B.A.C. Van Dijk et al.   EUROPEAN JOURNAL OF CANCER

Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options

(2011) Heidy C.J. Jaspers et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer

(2011) Peter S. Nelson   JOURNAL OF CLINICAL ONCOLOGY

Subtle variations in Pten dose determine cancer susceptibility

(2010) Andrea Alimonti et al.   NATURE GENETICS

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)

(2009) Laura D. Locati et al.   ORAL ONCOLOGY

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY